Saxenda for weight loss: Is the 'easy' experience real?

What did @thaysaventura actually say?

Honestly? It's hard to know. The transcript attached to this video is almost certainly a failed auto-transcription of Brazilian Portuguese audio — the output is incoherent English gibberish about kimchi, pizza, and "the top of the top of the bottom." What we can reliably extract is from the caption itself: @thaysaventura used Saxenda (liraglutide), tagged prediabetes and weight loss, and wrote that she expected it to be rough but it "wasn't that bad." That's the actual claim here — that starting Saxenda was more tolerable than anticipated. We cannot fact-check the transcript as speech because it does not represent what was said. We can, however, fact-check the experience she describes through her hashtags and caption.

Does the science back this up?

Actually, yes — for some people. Saxenda's side effect profile is real but variable, and a meaningful share of patients do tolerate it better than the online horror stories suggest. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that while nausea affected roughly 40% of liraglutide 3.0 mg users, most cases were mild to moderate and peaked in the first few weeks before subsiding. That same trial showed a 4.2% placebo-corrected weight loss at 56 weeks — modest but real. For prediabetes specifically, liraglutide reduced the risk of progression to type 2 diabetes by 80% over three years compared to placebo (le Roux et al., 2017, The Lancet). So the context of her hashtags — Saxenda used alongside a prediabetes diagnosis — is actually one of the better-supported use cases for this drug. Side effect severity varies widely by titration speed, individual gut sensitivity, and what you eat during the dose escalation period.

What did they get wrong (or right)?

They got the general sentiment right, even if we can't verify specific claims from the audio. Starting a GLP-1 agonist like liraglutide and finding it manageable is not a universal experience, but it is a documented one. Where creators like this sometimes go sideways is in implying that tolerability equals safety for everyone, or that a smooth personal experience means others won't struggle. Nausea, vomiting, and in rare cases pancreatitis are real risks documented in Saxenda's prescribing information. The SCALE trial also reported gallbladder events at higher rates in the liraglutide group. One thing worth noting: Saxenda is liraglutide dosed at up to 3.0 mg daily. It is a different drug from Ozempic or Wegovy (semaglutide). Creators mixing these up in their content — even implicitly through shared hashtags — contribute to public confusion about what these medications actually are and how they work differently.

What should you actually know?

Saxenda is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27-plus with at least one weight-related condition. Prediabetes qualifies as such a condition. That makes @thaysaventura's use case clinically legitimate, at least on paper. What nobody should take from a 30-second TikTok, though, is that their own experience will mirror hers. The titration schedule for liraglutide exists precisely because jumping to the full dose causes significantly more GI distress. A 2022 systematic review (Shi et al., Obesity Reviews) confirmed that slower titration correlates with better tolerance and lower discontinuation rates. If you are considering Saxenda or any GLP-1 agonist for prediabetes or weight management, that conversation belongs with a licensed provider who has reviewed your metabolic panel, not with an influencer's caption. Compounded liraglutide, which circulates on some telehealth platforms, is not the same as FDA-approved Saxenda. Do not assume equivalency.